Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study

Table 2 Risk factors for the primary outcome in patients with acute ischemic stroke and type 2 diabetes mellitus

	Adjusted OR [95% CI]	P value
Comorbidities
Hypertension	1.35 [1.28–1.43]	< 0.001
Atrial fibrillation	1.63 [1.56–1.71]	< 0.001
Malignancy	1.84 [1.75–1.93]	< 0.001
Renal disease	1.26 [1.21–1.30]	< 0.001
Coronary artery disease	1.19 [1.14–1.24]	< 0.001
Cardiovascular medication
Antiplatelet	0.73 [0.70–0.76]	< 0.001
Anticoagulant	0.62 [0.58–0.66]	< 0.001
Statin	0.63 [0.60–0.65]	< 0.001
Thiazolidinedione treatment
no thiazolidinedione	ref
Lobeglitazone	0.74 [0.61–0.90]	0.002
Pioglitazone	0.71 [0.64–0.78]	< 0.001

OR; odds ratio, CI; confidence interval
The primary outcome is defined as a composite of recurrent stroke, myocardial infarction, and all‑cause death after acute ischemic stroke
Data are derived from multivariable conditional logistic regression analysis adjusted for the listed comorbidities, the use of cardiovascular medications, and thiazolidinediones with the matched case-control dataset described in Table 1

ISSN: 1475-2840